Related Experiment Video
Updated: Jul 10, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
[Pharmacological protection against myocardial infarction: realities and actualities]
1Laboratoire de Pharmacologie, Inserm U 841/03, Faculté de médecine de Créteil, 8, rue du Général Sarrail, F 94010 Créteil Cedex. alain.berdeaux@creteil.inserm.fr
Insights
Pharmacological cardioprotection offers a complementary strategy to improve survival after myocardial infarction. While pre-clinical studies show promise, clinical relevance for reducing human heart attack mortality needs further investigation.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Context:
- Coronary heart disease and myocardial infarction are significant public health issues, with 120,000 annual cases in France.
- Early repermeabilization techniques reduce morbidity and mortality but are time-dependent for maximal myocardial protection.
- Delayed treatment limits the effectiveness of reperfusion in preventing myocardial necrosis.
Purpose:
- To explore pharmacological cardioprotection as an adjunct to reperfusion therapy for acute myocardial infarction.
- To review novel cardioprotection strategies based on pre- and postconditioning principles.
- To assess the clinical relevance and potential of these strategies in reducing human myocardial infarction outcomes.
Summary:
- Pharmacological cardioprotection aims to enhance myocardial survival by mitigating ischemic injury.
- New strategies leverage knowledge of pathological, physiological, and pharmacological processes in pre- and postconditioning.
- Pre-clinical efficacy has been demonstrated, but clinical validation is pending.
Impact:
- Pharmacological cardioprotection could complement existing reperfusion therapies.
- Further research is needed to establish the clinical utility of these approaches.
- Successful translation may reduce morbidity and mortality associated with myocardial infarction.
Abstract:
Coronary heart disease and myocardial infarction remain a major problem of public health with an annual incidence of 120,000 cases in France. Although several techniques of early repermeabilization of the obstructed coronary arteries have been available for almost twenty years with an associated high degree of reduction in morbidity and mortality of post-infarction patients, such success still remains dependent on the delay to the procedure to enable maximal protection of the myocardium against necrosis. Thus, pharmacological "cardioprotection" against ischemic injury must be considered as an additional and complementary opportunity to enhance myocardial survival following acute infarction. On the basis of current knowledge of the pathological, physiological and pharmacological processes involved in pre- and postconditioning, new strategies of cardioprotection associated with reperfusion of the myocardium have been proposed in recent years. The efficacy of these new approaches has been proven pre-clinically using experimental models but their real clinical relevance and their ability to reduce human myocardial infarction-associated morbidity and mortality remains to be determined.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:26Atherosclerosis III: Management
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...